Exploitz traded like a focused Solana scalper over the last 30 days, rotating through just 4 tokens across 10 trades. The wallet’s average holding time was 1,493 seconds, which points to short-duration execution rather than longer conviction swings. Activity was concentrated, with only a small token set and repeated attempts in the same names, suggesting a tight watchlist and a preference for fast entries and exits. For traders reviewing copy potential, this wallet currently reads as a high-frequency, narrow-scope operator rather than a broad market participant.
Recent performance was weak across the full window. Exploitz posted -$275.91 in PnL on $740.31 in total buys and $464.4 in total sells, resulting in -37.27% ROI. The win rate was 0% over 10 trades, which means none of the tracked trades closed green in this period. With only 4 unique tokens traded, the losses were not spread across a wide set of experiments; they came from a relatively concentrated approach. That matters because it shows the negative result was tied to repeated execution within a small basket, not just one-off misses across many assets.
The token-level breakdown also shows a fairly even distribution of losses rather than a single catastrophic trade. The worst result came from E95s… at -$93.9 over 2 trades. H2PR… followed at -$66.38 over 2 trades, and 2nSP… at -$62.26 over 2 trades. Even the best-performing token, 8EyA…, still lost -$53.36 despite accounting for 4 trades. This pattern suggests Exploitz kept pressing similar setups, but none of the names delivered a profitable outcome during the measured period.
This wallet would mainly appeal to traders specifically looking to mirror a very short-term scalping style with a focused token list and frequent re-engagement in the same plays. It is less suitable for someone seeking diversified exposure, slower holding periods, or a recent track record of positive closes. Based on the last 30 days alone, Exploitz looks most relevant to observers who want to study concentrated, rapid trading behavior on Solana, while accepting that the recent results were consistently negative.